Everything tagged "growth" across research, earnings, and macro.
192 articles
Arrowhead is transitioning from platform biotech to commercial-stage RNAi company, with REDEMPLO launch traction, a fortified balance sheet, and a deep partnered pipeline. The stock still depends on execution, but the setup is constructive for medium-term investors.
Philip Morris International is evolving from a cigarette cash cow into a smoke-free growth story, with reduced-risk products now approaching half of revenue. Strong execution in IQOS and other nicotine alternatives supports the Buy case, though leverage and valuation keep upside measured.
Wabtec combines a growing installed base, strong aftermarket mix, and a $30.8B backlog with improving margins. The main debate is valuation, not business quality.
FICO combines an elite Scores franchise with a fast-growing platform software business, but the stock already prices in a lot of that strength. Mortgage exposure and credit-score modernization remain the key risks.
Danaher is seeing better operating momentum across Life Sciences, Diagnostics, and Biotechnology, but the stock still trades at a premium that limits upside. The report keeps a Buy rating with fair value set at $225.
Texas Instruments posted strong Q1 2026 growth and is seeing industrial and data center demand improve, but the stock already prices in much of the recovery. The company’s manufacturing edge and broad analog franchise support the long-term case, yet valuation keeps the stance at Hold.
TE Connectivity is benefiting from record orders, accelerating Industrial Solutions growth, and rising exposure to AI infrastructure and power networks. Strong cash generation and reasonable valuation support a Buy case.
Moody’s combines a subscription-heavy analytics business with a high-margin ratings franchise, creating a durable compounder with strong cash generation. The stock looks attractive on quality, but its premium valuation keeps the upside measured.
United Rentals is a scaled industrial compounder with strong specialty-rental momentum, but its premium valuation and heavy debt keep the upside measured. The stock earns a Buy on durable execution and raised 2026 guidance.
Medpace is still delivering strong revenue, margin, and cash flow growth, but softer bookings and a rich valuation keep the stock in Hold territory. The business quality is high, yet the current setup looks better on pullbacks than at full price.
United Airlines is showing stronger pricing power, premium demand, and loyalty monetization while still trading at a modest earnings multiple. The balance sheet remains leveraged, but improving liquidity and a better operating model support a Buy view.
Interactive Brokers is a high-quality, automation-led brokerage franchise with strong account growth, elite margins, and a pristine balance sheet. The stock looks attractive as a Buy, but valuation and rate sensitivity argue for discipline.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator